Table 2.

Unadjusted association between patients' characteristics and PSA results

PSA orderedPSA conductedPSA≥4 ng/mL
NN (%)aP valueN (%)bP valueN (%)cP value
All patients9,2672,525 (27.2)2,486 (26.8)141 (5.7)
Race ethnicity<0.001<0.0010.001
 African-American632181 (28.6)178 (28.2)22 (12.4)
 Non-Hispanic white2,470529 (21.4)517 (20.9)28 (5.4)
 Hispanic5,8761,738 (29.6)1,717 (29.2)87 (5.1)
 Other28977 (26.6)74 (25.6)4 (5.4)
Benign prostatic hyperplasia<0.001<0.0010.06
 Yes516229 (44.4)226 (43.8)19 (8.4)
 No8,7512,295 (26.2)2,260 (25.8)122 (5.4)
No. of non–prostate-related clinical conditions<0.001<0.0010.31
 01,961461 (23.5)449 (22.9)24 (5.3)
 12,637758 (28.7)748 (28.4)51 (6.8)
 23,028852 (28.1)843 (27.8)47 (5.6)
≥31,641454 (27.7)446 (27.2)19 (4.3)
Insurance type<0.001<0.0010.12
 CareLink A1,154328 (28.4)322 (27.9)11 (3.4)
 CareLink Other3,041953 (31.3)941 (30.9)57 (6.1)
 Medicaid789190 (24.1)185 (23.4)6 (3.2)
 Medicare2,550654 (25.6)644 (25.3)47 (7.3)
 Private/state agency1,425356 (25.0)353 (24.8)18 (5.1)
 Other30844 (14.3)41 (13.3)2 (4.9)
  • aProportion of men had a PSA ordered.

  • bProportion of men had a PSA conducted.

  • cProportion of men had an abnormal PSA among those who had a PSA conducted.